Literature DB >> 7103458

Anti-influenza A virus activity of amantadine hydrochloride and rimantadine hydrochloride in ferret tracheal ciliated epithelium.

D B Burlington, G Meiklejohn, S R Mostow.   

Abstract

The activities and toxicities of amantadine hydrochloride and rimantadine hydrochloride against influenza A/Alaska/6/77 (H3N2) and A/Bangkok/1/79 (H3N2) viruses were compared in organ cultures and ferret tracheal ciliated epithelium. Pretreatment of cultures with concentrations (0.5 and 1 micrograms/ml) comparable to those found in human serum after oral administration of amantadine revealed that rimantadine produced significantly longer protection than amantadine against virus-induced cytopathic effects. Correspondingly, rimantadine produced a comparable protective effect at four- to eight-fold-lower concentrations than amantadine. Both drugs produced increasing and similar effects at higher concentrations, which were comparable to those reported in nasal washings after aerosol administration of amantadine. At the concentrations tested, amantadine was nontoxic. However, at concentrations of 16 and 32 micrograms/ml, rimantadine was toxic to the ciliated epithelium after 10 to 21 days of continuous exposure. When the drugs were added 24 h or more after infection, protection against cytopathic effects decreased markedly. Both drugs moderately suppressed virus production at concentrations of 0.5 to 16 micrograms/ml. However, no dose response or difference between the drugs was observed. Because of comparable antiviral activity at lower concentrations and greater activity at similar concentrations, rimantadine may be more useful than amantadine for oral prophylaxis and therapy of influenza.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7103458      PMCID: PMC182013          DOI: 10.1128/AAC.21.5.794

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  30 in total

Review 1.  Specific inhibitors of influenza virus replication as potential chemoprophylactic agents.

Authors:  J S Oxford
Journal:  J Antimicrob Chemother       Date:  1975-03       Impact factor: 5.790

2.  Viruses causing common respiratory infections in man. V. influenza A (Asian).

Authors:  G G Jackson; R L Muldoon
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

3.  Small-particle aerosols of antiviral compounds in treatment of type A influenza pneumonia in mice.

Authors:  J S Walker; E L Stephen; R O Spertzel
Journal:  J Infect Dis       Date:  1976-06       Impact factor: 5.226

4.  Influenza and the interaction of viruses and bacteria in respiratory infections.

Authors:  C G Loosli
Journal:  Medicine (Baltimore)       Date:  1973-09       Impact factor: 1.889

5.  Protection of man from natural infection with influenza A2 Hong Kong virus by amantadine: a controlled field trial.

Authors:  N Oker-Blom; T Hovi; P Leinikki; T Palosuo; R Pettersson; J Suni
Journal:  Br Med J       Date:  1970-09-19

6.  Therapeutic efficacy of amantadine HCl and rimantadine HCl in naturally occurring influenza A2 respiratory illness in man.

Authors:  W L Wingfield; D Pollack; R R Grunert
Journal:  N Engl J Med       Date:  1969-09-11       Impact factor: 91.245

7.  Treatment of influenza. The therapeutic efficacy of rimantadine HC1 in a naturally occurring influenza A2 outbreak.

Authors:  S Rabinovich; J T Baldini; R Bannister
Journal:  Am J Med Sci       Date:  1969-05       Impact factor: 2.378

8.  Human influenza resulting from aerosol inhalation.

Authors:  R H Alford; J A Kasel; P J Gerone; V Knight
Journal:  Proc Soc Exp Biol Med       Date:  1966-07

9.  Use and withdrawal of amantadine chemoprophylaxis during epidemic influenza A.

Authors:  R L Muldoon; E D Stanley; G G Jackson
Journal:  Am Rev Respir Dis       Date:  1976-04

10.  The behaviour in vitro of attenuated recombinant influenza viruses.

Authors:  S R Mostow; D A Tyrrell
Journal:  Arch Gesamte Virusforsch       Date:  1973
View more
  5 in total

1.  Safety and pharmacokinetics of rimantadine small-particle aerosol.

Authors:  R L Atmar; S B Greenberg; J M Quarles; S Z Wilson; B Tyler; S Feldman; R B Couch
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

2.  Serum concentrations and safety of rimantadine in paediatric patients.

Authors:  M C Nahata; M T Brady
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 3.  Antiviral therapy: respiratory infections, chronic hepatitis.

Authors:  B I Asmar; N M Abdel-Haq
Journal:  Indian J Pediatr       Date:  2001-07       Impact factor: 5.319

Review 4.  Antiviral chemotherapy and prophylaxis of viral respiratory disease.

Authors:  S J Sperber; F G Hayden
Journal:  Clin Lab Med       Date:  1987-12       Impact factor: 1.935

Review 5.  A Critical Review of Disinfection Processes to Control SARS-CoV-2 Transmission in the Food Industry.

Authors:  Adrián Pedreira; Yeşim Taşkın; Míriam R García
Journal:  Foods       Date:  2021-01-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.